227 related articles for article (PubMed ID: 19449004)
1. The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells.
Smits EL; Cools N; Lion E; Van Camp K; Ponsaerts P; Berneman ZN; Van Tendeloo VF
Cancer Immunol Immunother; 2010 Jan; 59(1):35-46. PubMed ID: 19449004
[TBL] [Abstract][Full Text] [Related]
2. The role of TLR8 signaling in acute myeloid leukemia differentiation.
Ignatz-Hoover JJ; Wang H; Moreton SA; Chakrabarti A; Agarwal MK; Sun K; Gupta K; Wald DN
Leukemia; 2015 Apr; 29(4):918-926. PubMed ID: 25283842
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of Toll-like receptor 4 and 7/8 agonists is necessary to generate potent blast-derived dendritic cells in Acute Myeloid Leukemia.
Nourizadeh M; Masoumi F; Memarian A; Alimoghaddam K; Moazzeni SM; Hadjati J
Leuk Res; 2012 Sep; 36(9):1193-9. PubMed ID: 22579107
[TBL] [Abstract][Full Text] [Related]
4. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
Vasilakos JP; Tomai MA
Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
6. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.
Johnson TR; Rao S; Seder RA; Chen M; Graham BS
Vaccine; 2009 May; 27(23):3045-52. PubMed ID: 19428918
[TBL] [Abstract][Full Text] [Related]
7. Conjugation of TLR7 Agonist Combined with Demethylation Treatment Improves Whole-Cell Tumor Vaccine Potency in Acute Myeloid Leukemia.
Zhong G; Jin G; Zeng W; Yu C; Li Y; Zhou J; Zhang L; Yu L
Int J Med Sci; 2020; 17(15):2346-2356. PubMed ID: 32922200
[No Abstract] [Full Text] [Related]
8. Accessory-cell-mediated activation of porcine NK cells by toll-like receptor 7 (TLR7) and TLR8 agonists.
Toka FN; Nfon CK; Dawson H; Golde WT
Clin Vaccine Immunol; 2009 Jun; 16(6):866-78. PubMed ID: 19369481
[TBL] [Abstract][Full Text] [Related]
9. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy.
Kim H; Niu L; Larson P; Kucaba TA; Murphy KA; James BR; Ferguson DM; Griffith TS; Panyam J
Biomaterials; 2018 May; 164():38-53. PubMed ID: 29482062
[TBL] [Abstract][Full Text] [Related]
10. Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation.
van den Ancker W; van Luijn MM; Ruben JM; Westers TM; Bontkes HJ; Ossenkoppele GJ; de Gruijl TD; van de Loosdrecht AA
Cancer Immunol Immunother; 2011 Jan; 60(1):37-47. PubMed ID: 20859626
[TBL] [Abstract][Full Text] [Related]
11. The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation.
Hackstein H; Knoche A; Nockher A; Poeling J; Kubin T; Jurk M; Vollmer J; Bein G
Cell Immunol; 2011; 271(2):401-12. PubMed ID: 21889130
[TBL] [Abstract][Full Text] [Related]
12. TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity.
Du J; Wu Z; Ren S; Wei Y; Gao M; Randolph GJ; Qu C
Vaccine; 2010 Aug; 28(38):6273-81. PubMed ID: 20637759
[TBL] [Abstract][Full Text] [Related]
13. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.
Spranger S; Javorovic M; Bürdek M; Wilde S; Mosetter B; Tippmer S; Bigalke I; Geiger C; Schendel DJ; Frankenberger B
J Immunol; 2010 Jul; 185(1):738-47. PubMed ID: 20511554
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
15. Activation of Human γδ T Cells: Modulation by Toll-Like Receptor 8 Ligands and Role of Monocytes.
Serrano R; Wesch D; Kabelitz D
Cells; 2020 Mar; 9(3):. PubMed ID: 32183240
[TBL] [Abstract][Full Text] [Related]
16. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.
Gorden KB; Gorski KS; Gibson SJ; Kedl RM; Kieper WC; Qiu X; Tomai MA; Alkan SS; Vasilakos JP
J Immunol; 2005 Feb; 174(3):1259-68. PubMed ID: 15661881
[TBL] [Abstract][Full Text] [Related]
17. TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells.
Jähnisch H; Wehner R; Tunger A; Kunze A; Oehrl S; Schäkel K; Rohayem J; Bornhäuser M; Tonn T; Bachmann M; Schmitz M
Cancer Lett; 2013 Jul; 335(1):119-27. PubMed ID: 23402811
[TBL] [Abstract][Full Text] [Related]
18. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.
Wang D; Precopio M; Lan T; Yu D; Tang JX; Kandimalla ER; Agrawal S
Mol Cancer Ther; 2010 Jun; 9(6):1788-97. PubMed ID: 20515950
[TBL] [Abstract][Full Text] [Related]
20. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.
Fahey LM; Raff AB; Da Silva DM; Kast WM
J Immunol; 2009 Mar; 182(5):2919-28. PubMed ID: 19234187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
